Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A8QM
|
||||
| Former ID |
DIB014156
|
||||
| Drug Name |
Lu-AA34893
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Phase 2 | [1] | ||
| Company |
H Lundbeck A/S
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Modulator | [2] | |
| 5-hydroxytryptamine receptor | Target Info | Modulator | [2] | ||
| KEGG Pathway | Serotonergic synapse | ||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00622245) Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression. U.S. National Institutes of Health. | ||||
| REF 2 | Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.